Brief: Unicycive Therapeutics Issues Shareholder Letter To Highlight Corporate Progress And Key Upcoming Milestones
23/01/2024 12:16
Jan 23 (Reuters) - Unicycive Therapeutics Inc UNCY.O :
* UNICYCIVE THERAPEUTICS ISSUES SHAREHOLDER LETTER TO
HIGHLIGHT
CORPORATE PROGRESS AND KEY UPCOMING MILESTONES
* UNICYCIVE THERAPEUTICS INC - TOPLINE DATA FROM OLC PIVOTAL
TRIAL
EXPECTED IN Q2 2024
* UNICYCIVE THERAPEUTICS INC - WILL REPORT OUT OUR PIVOTAL
DATA
FOR OLC NEXT QUARTER AND PLAN TO COMPLETE OUR DATA PACKAGE AND
SUBMIT AN NDA MID-YEAR
Source text for Eikon: ID:nGNX9tB5hH
Further company coverage: UNCY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Unicycive Therapeutics
See all newsBrief: Unicycive Therapeutics Appoints Meredith Manning To Board Of Directors
Brief: Unicycive Therapeutics Announces Resubmission Of New Drug Application For Oxylanthanum Carbonate
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
Unicycive rises on narrower quarterly loss